HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Dai, Kaifan ^a,b   Khan, Salar N ^a,b   Wang, Yimeng ^b   He, Linling ^b   Guenaga, Javier ^a,b   Ingale, Jidnyasa ^a,b   Sundling, Christopher ^c   O'Dell, Sijy ^d   McKee, Krisha ^d   Phad, Ganesh ^c   Corcoran, Martin ^c   Wilson, Richard ^a,b   Mascola, John R ^d   Zhu, Jiang ^a,b   Li, Yuxing ^a,b   Hedestam, Gunilla B Karlsson ^c   Wyatt, Richard T ^a,b  

^a ILTAB   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Vaccine Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COMPLEMENTARITY DETERMINING REGION; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN BINDING; VIRUS ENVELOPE PROTEIN;

ANIMAL; ANTIBODY SPECIFICITY; B LYMPHOCYTE; CHEMISTRY; COMPLEMENTARITY DETERMINING REGION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGY; KINETICS; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION; RHESUS MONKEY; SERODIAGNOSIS; SURFACE PLASMON RESONANCE;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTIGENS, CD4; B-LYMPHOCYTES; COMPLEMENTARITY DETERMINING REGIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNIZATION; KINETICS; MACACA MULATTA; MODELS, MOLECULAR; NEUTRALIZATION TESTS; PROTEIN BINDING; PROTEIN CONFORMATION; SURFACE PLASMON RESONANCE;

EID: 84958267857     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20987     Document Type: Article

References (54)

1. Wu, L. et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384, 179-83 (1996).
2. Deng, H. et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-6 (1996).
3. Choe, H. et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135-48 (1996).
4. Chan, D. C., Fass, D., Berger, J. M., Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-73 (1997).
5. Wyatt, R., Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884-8 (1998).
6. Karlsson Hedestam, G. B. et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6, 143-55 (2008).
7. Forsell, M. N., Schief, W. R., Wyatt, R. T. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr Opin HIV AIDS 4, 380-7 (2009).
8. Chakrabarti, B. K. et al. Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. J Virol 87, 13239-51 (2013).
9. Sharma, S. K. et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep 11, 539-50 (2015).
10. Mascola, J. R., Montefiori, D. C. The role of antibodies in HIV vaccines. Annu Rev Immunol 28, 413-44 (2010).
11. Burton, D. R., Poignard, P., Stanfield, R. L., Wilson, I. A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337, 183-6 (2012).
12. Stamatatos, L., Morris, L., Burton, D. R., Mascola, J. R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15, 866-70 (2009).
13. Li, Y. et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13, 1032-4 (2007).
14. Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-9 (2009).
15. Corti, D. et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5, e8805 (2010).
16. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-61 (2010).
17. Falkowska, E. et al. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol 86, 4394-403 (2012).
18. Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-7 (2011).
19. Jardine, J. et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711-6 (2013).
20. McGuire, A. T. et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 210, 655-63 (2013).
21. Hoot, S. et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 9, e1003106 (2013).
22. Haynes, B. F., Kelsoe, G., Harrison, S. C., Kepler, T. B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 30, 423-33 (2012).
23. Xiao, X. et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 390, 404-9 (2009).
24. Jardine, J. G. et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349, 156-61 (2015).
25. Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-7 (2010).
26. Georgiev, I. S., Gordon Joyce, M., Zhou, T., Kwong, P. D. Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Curr Opin HIV AIDS 8, 382-92 (2013).
27. Shih, T. A., Meffre, E., Roederer, M., Nussenzweig, M. C. Role of BCR affinity in T cell dependent antibody responses in vivo. Nat Immunol 3, 570-5 (2002).
28. Dal Porto, J. M., Haberman, A. M., Kelsoe, G., Shlomchik, M. J. Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced. J Exp Med 195, 1215-21 (2002).
29. Julien, J. P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477-83 (2013).
30. Sundling, C. et al. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med 4, 142-96 (2012).
31. Sundling, C., Phad, G., Douagi, I., Navis, M., Karlsson Hedestam, G. B. Isolation of antibody V(D)J sequences from single cell sorted rhesus macaque B cells. J Immunol Methods 386, 85-93 (2012).
32. Navis, M. et al. HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization. PLoS Pathog 10, e1004337 (2014).
33. Ylera, F., Harth, S., Waldherr, D., Frisch, C., Knappik, A. Off-rate screening for selection of high-affinity anti-drug antibodies. Anal Biochem 441, 208-13 (2013).
34. Bates, J. T. et al. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein. Virology 454-455, 139-44 (2014).
35. Bates, J. T. et al. Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency. J Immunol 190, 3732-9 (2013).
36. Tran, K. et al. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci USA 111, E738-47 (2014).
37. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., Sternberg, M. J. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 10, 845-58 (2015).
38. Brenke, R. et al. Application of asymmetric statistical potentials to antibody-protein docking. Bioinformatics 28, 2608-14 (2012).
39. Howard, W. A., Bible, J. M., Finlay-Dijsselbloem, E., Openshaw, S., Dunn-Walters, D. K. Immunoglobulin light-chain genes in the rhesus macaque II: lambda light-chain germline sequences for subgroups IGLV1, IGLV2, IGLV3, IGLV4 and IGLV5. Immunogenetics 57, 655-64 (2005).
40. Howard, W. A., Bible, J. M., Finlay-Dijsselbloem, E., Openshaw, S., Dunn-Walters, D. K. Immunoglobulin light-chain genes in the rhesus macaque I: kappa light-chain germline sequences for subgroups IGKV1, IGKV and IGKV3. Immunogenetics 57, 210-8 (2005).
41. Thullier, P., Chahboun, S., Pelat, T. A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering. MAbs 2, 528-38 (2010).
42. Francica, J. R. et al. Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plusadjuvant immunization. Nat Commun 6, 6565 (2015).
43. Warren, J. Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates. J Med Primatol 31, 237-56 (2002).
44. Carlsson, H. E., Schapiro, S. J., Farah, I., Hau, J. Use of primates in research: a global overview. Am J Primatol 63, 225-37 (2004).
45. Gao, F. et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 158, 481-91 (2014).
46. Liao, H. X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469-76 (2013).
47. Doria-Rose, N. A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55-62 (2014).
48. Sastre, P. et al. Seroprevalence of human respiratory syncytial virus and human metapneumovirus in healthy population analyzed by recombinant fusion protein-based enzyme linked immunosorbent assay. Virol J 9, 130 (2012).
49. Luchsinger, V. et al. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis 54, 905-12 (2012).
50. Victora, G. D. SnapShot: the germinal center reaction. Cell 159, 700-700 e1 (2014).
51. Sundling, C. et al. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med 207, 2003-17 (2010).
52. He, L. et al. Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding. Sci Rep 4, 6778 (2014).
53. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79, 10108-25 (2005).
54. Chakrabarti, B. K. et al. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J Virol 85, 8217-26 (2011).